利妥昔单抗治疗成人难治性原发性膜性肾病的临床分析
|
|
冯琳鸿, 王亚琨, 吴茜茜, 朱迎春, 白寿军
|
Clinical analysis of rituximab for adult refractory primary membranous nephropathy
|
|
FENG Linhong, WANG Yakun, WU Qianqian, ZHU Yingchun, BAI Shoujun
|
|
表3 18例难治性PMN患者接受RTX治疗情况及疗效评价
|
Tab 3 RTX treatment and efficacy evaluation of 18 patients with refractory PMN
|
|
| Efficacy evaluation after RTX | No. | Follow-up time after RTX/month | Time to achieve complete/partial relief/month | RTX total dose/mg |
|---|
| Complete relief | 1 | 12 | 10 | 2 000 | | 2 | 14 | 12 | 2 000 | | 5 | 14 | 14 | 2 000 | | 7 | 18 | 17 | 2 000 | | 8 | 14 | 14 | 3 000 | | 9 | 11 | 10 | 2 000 | | 12 | 28 | 24 | 3 000 | | 18 | 7 | 7 | 2 000 | | Partial relief | 3 | 12 | 12 | 2 000 | | 4 | 12 | 12 | 2 000 | | 10 | 14 | 13 | 2 000 | | 11 | 24 | 24 | 3 000 | | 14 | 15 | 13 | 2 000 | | 16 | 13 | 12 | 3 000 | | 17 | 12 | 12 | 2 000 | | Unrelieved | 6 | 20 | - | 3 000 | | 13 | 12 | - | 2 000 | | 15 | 17 | - | 3 000 |
|
|
|